Myasthenia gravis and scleroderma: Two cases and a review of the literature

Clinical Neurology and Neurosurgery

Volumn 109, Issue 4, 2007, Pages 388-391

  Živković, Saša A ^a,b   Medsger Jr , Thomas A ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

d Penicillamine; Localized scleroderma; Myasthenia gravis; Scleroderma; Systemic sclerosis

Indexed keywords

ALENDRONIC ACID; CALCIUM; CELECOXIB; CLONAZEPAM; EDROPHONIUM; GABAPENTIN; HYDROXYCHLOROQUINE; LANSOPRAZOLE; LEVOTHYROXINE; METFORMIN; MIRTAZAPINE; PENICILLAMINE; PREDNISONE; PYRIDOSTIGMINE; RANITIDINE; SUMATRIPTAN; TRAZODONE;

ADULT; ANAMNESIS; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CLINICAL FEATURE; DRUG DOSE REDUCTION; EYE MOVEMENT; FEMALE; HASHIMOTO DISEASE; HUMAN; LABORATORY TEST; LATENT PERIOD; MYASTHENIA GRAVIS; NEUROLOGIC EXAMINATION; PATIENT SELECTION; PTOSIS; RISK; SCLERODERMA; SERODIAGNOSIS; TENDON REFLEX;

ADULT; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; COMORBIDITY; FOLLOW-UP STUDIES; HASHIMOTO DISEASE; HUMANS; MIDDLE AGED; MYASTHENIA GRAVIS; NEUROLOGIC EXAMINATION; PENICILLIC ACID; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; SJOGREN'S SYNDROME; THYMECTOMY; THYMUS HYPERPLASIA;

EID: 33947304476     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2007.01.006     Document Type: Article

References (30)

1. LeRoy E.C., Black C., Fleischmajer R., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15 2 (1988) 202-205
2. Peterson L.S., Nelson A.M., and Su W.P. Classification of morphea (localized scleroderma). Mayo Clin Proc 70 11 (1995) 1068-1076
3. Averbuch-Heller L., Steiner I., and Abramsky O. Neurologic manifestations of progressive systemic sclerosis. Arch Neurol 49 12 (1992) 1292-1295
4. Marzano A.V., Menni S., Parodi A., et al. Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases. Eur J Dermatol 13 2 (2003) 171-176
5. Thorlacius S., Aarli J.A., Riise T., Matre R., and Johnsen H.J. Associated disorders in myasthenia gravis: autoimmune diseases and their relation to thymectomy. Acta Neurol Scand 80 4 (1989) 290-295
6. Steen V.D., Blair S., and Medsger Jr. T.A. The toxicity of d-penicillamine in systemic sclerosis. Ann Intern Med 104 5 (1986) 699-705
7. Keesey J.C. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 29 4 (2004) 484-505
8. de Wazieres B., Fraisse T.C., di Castri A., Damigny A., and Fourcade J. Myasthenia associated with systemic scleroderma. Rev Med Intern 23 4 (2002) 403-404
9. Ben-Shahar M., Rosenblatt E., Green J., and Cohen I. Malignant thymoma associated with progressive systemic sclerosis. Am J Med Sci 294 4 (1987) 262-267
10. Peterson L.S., Nelson A.M., Su W.P., Mason T., O'Fallon W.M., and Gabriel S.E. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. J Rheumatol 24 1 (1997) 73-80
11. Steen V.D., Oddis C.V., Conte C.G., Janoski J., Casterline G.Z., and Medsger Jr. T.A. Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963-1982. Arthritis Rheum 40 3 (1997) 441-445
12. Vincent A., McConville J., Farrugia M.E., et al. Antibodies in myasthenia gravis and related disorders. Ann N Y Acad Sci 998 (2003) 324-335
13. Drosos A.A., Christou L., Galanopoulou V., Tzioufas A.G., and Tsiakou E.K. d-Penicillamine induced myasthenia gravis: clinical, serological and genetic findings. Clin Exp Rheumatol 11 4 (1993) 387-391
14. Hibino N., and Takegami T. Systemic sclerosis complicated with left trigeminal neuropathy and myasthenia gravis during a period of six years after onset. Nippon Naika Gakkai Zasshi 92 12 (2003) 2423-2425
15. Kim H.S., Chun Y.S., Hann S.K., and Park W.H. A case of linear scleroderma and myasthenia gravis. J Dermatol 27 1 (2000) 31-34
16. Aldrich M.S., Kim Y.I., and Sanders D.B. Effects of d-penicillamine on neuromuscular transmission in rats. Muscle Nerve 2 3 (1979) 180-185
17. Kuncl R.W., Pestronk A., Drachman D.B., and Rechthand E. The pathophysiology of penicillamine-induced myasthenia gravis. Ann Neurol 20 6 (1986) 740-744
18. Penn A.S., Low B.W., Jaffe I.A., Luo L., and Jacques J.J. Drug-induced autoimmune myasthenia gravis. Ann N Y Acad Sci 841 (1998) 433-449
19. Steen V.D., and Medsger Jr. T.A. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 44 12 (2001) 2828-2835
20. Cush J.J., and Goldings E.A. Drug-induced lupus: clinical spectrum and pathogenesis. Am J Med Sci 290 1 (1985) 36-45
21. Davis Jr. J.C. Breaking the ice: testing tumor necrosis factor alpha blockade in lupus. Arthritis Rheum 50 10 (2004) 3061-3063
22. Arostegui J., Gorordo J.M., and Aramburu J.M. Myasthenia gravis and scleroderma. J Rheumatol 22 4 (1995) 792-793
23. Bhalla R., Swedler W.I., Lazarevic M.B., Ajmani H.S., and Skosey J.L. Myasthenia gravis and scleroderma. J Rheumatol 20 8 (1993) 1409-1410
24. Hausmanowa-Petrusewicz I., Blaszczyk M., and Jablonska S. Coexistence of scleromyositis associated with PM-Scl antibody and myasthenia. Neuromuscul Disord 5 2 (1995) 145-147
25. Kambara C., Kinoshita I., Amenomori T., Eguchi K., and Yoshimura T. Myasthenia gravis associated with limited scleroderma (CREST syndrome). J Neurol 247 1 (2000) 61-62
26. Mitchell G.W., Lichtenfeld P.J., and McDonald C.J. Myasthenia gravis and scleroderma. An unusual combination of diseases. JAMA 233 6 (1975) 531
27. Parra V., Driban N., and Basotti A. Localized morphea and myasthenia gravis [e-pub]. J Am Acad Dermatol 49 (2003) e5 [Accessed 10/30/2006]
28. Uono M., Irie M., Minoda K., and Sakimoto T. Case of myasthenia gravis fing thyroidectomy in Basedow's disease and later complicated by systemic sclerosis. Shinkei Kenkyu No Shimpo 15 4 (1971) 819-823
29. Werneck A.L., Checcacci-Balod T., and Tuma G. Scleroderma, thyroiditis, and myasthenia gravis: study of a case. Arq Neuropsiquiatr 51 4 (1993) 549-553
30. Ferri C., Colaci M., Battolla L., Giuggioli D., and Sebastiani M. Thymus alterations and systemic sclerosis. Rheumatology (Oxford) 45 1 (2006) 72-75